A groundbreaking Australian study has unveiled a promising new avenue in the fight against sepsis, one of the nation's leading causes of preventable death. Researchers from the University of Adelaide and the Central Adelaide Local Health Network have demonstrated that a naturally occurring protein known as corticosteroid-binding globulin (CBG)—the body's primary carrier for the anti-inflammatory hormone cortisol—could dramatically improve outcomes for patients suffering from septic shock when administered therapeutically. Published in the prestigious journal Endocrinology on January 12, 2026, this landmark research marks a potential paradigm shift after decades without significant advances in sepsis treatment.

Sepsis affects tens of thousands of Australians annually, with recent data indicating over 84,000 hospitalizations in 2022-23 alone and more than 8,700 deaths each year—outpacing road accident fatalities. In intensive care units, septic shock, the most severe form, carries a mortality rate approaching 30-50%, underscoring the urgent need for innovative therapies. This study's revelation that replenishing depleted CBG levels slashed mortality by over 70% in preclinical models offers tangible hope, positioning CBG as a novel natural anti-inflammatory agent untapped for over half a century.

The Hidden Crisis of Sepsis in Australia

Sepsis, formally defined as life-threatening organ dysfunction caused by a dysregulated host response to infection (Sepsis-3 definition from the Society of Critical Care Medicine), begins as a localized infection—often pneumonia, urinary tract infections, or abdominal sources—but escalates when the immune system unleashes a cytokine storm. This overzealous inflammation damages healthy tissues, leading to vascular leakage, hypotension, and multi-organ failure characteristic of septic shock.

In Australia, the burden is stark: the Australian Commission on Safety and Quality in Health Care reports sepsis as the 10th leading cause of death, with 1 in 7 hospitalized patients succumbing and survivors facing prolonged recovery, repeat admissions, and chronic issues like post-sepsis syndrome. Indigenous Australians and those with comorbidities like diabetes (affecting 1 in 3 cases) bear disproportionate risks. Despite antibiotics and supportive care like fluids and vasopressors, no targeted immunomodulatory therapy has emerged since the 1950s, highlighting why CBG represents such a breakthrough.

The study's genesis traces back 13 years to observations at Royal Adelaide Hospital, where low CBG levels correlated with threefold higher mortality in septic shock patients. This clinical insight propelled preclinical validation using the gold-standard cecal ligation and puncture (CLP) mouse model, mimicking human polymicrobial sepsis.

Unveiling CBG: The Body's Overlooked Guardian

Corticosteroid-binding globulin (CBG), a 50-60 kDa glycoprotein synthesized primarily in the liver, binds over 90% of circulating cortisol (hydrocortisone), the endogenous glucocorticoid pivotal for stress responses. Under normal conditions, CBG maintains cortisol in an inactive reservoir, releasing it at inflamed sites via proteolytic cleavage—activated by neutrophil elastase or pyrexia-induced conformational changes.

In sepsis, however, CBG plummets, unleashing free cortisol yet failing to quell the inflammatory cascade. The Adelaide team's innovation: intravenous native human CBG supplementation. In CLP mice (n=106, instrumented with arterial telemetry), therapy at 6 hours (3.5 mg/kg) and 30 hours (2.5 mg/kg) post-induction yielded transformative results. Mortality dropped from 58% to 17%, hypotension duration halved (75% reduction), and biomarkers of kidney, liver, and lung injury plummeted.

Positron emission tomography (PET) with ¹²⁴I-labeled CBG confirmed targeted accumulation at injury sites, suggesting direct immunomodulation. Cytokine profiling revealed transient suppression of pro-inflammatory IL-6, TNF-α (45-59% at 12 hours), and sustained elevation of anti-inflammatory IL-10 and IFN-β (up to 96-fold), independent of cortisol levels—hinting at novel receptor-mediated pathways.

Preclinical Triumph: Step-by-Step Breakdown of the Experiment

The study's rigor exemplifies translational research at the University of Adelaide. Adult male C57BL/6 mice underwent wireless telemetry implantation for real-time blood pressure monitoring. High-grade CLP induced polymicrobial peritonitis, replicating human septic shock: fever, leukocytosis, and progressive organ failure.

• Hour 0: Sepsis induction via cecal puncture.
• Hours 6 & 30: Randomized CBG infusion (saline controls).
• Monitoring to 96 hours or humane endpoint: Survival, hemodynamics, cytokines (ELISA/multiplex), organ histology (H&E scoring), PET biodistribution.

CBG not only rescued hemodynamics but preserved organ architecture, with reduced neutrophil infiltration and apoptosis. No toxicity noted, even at supra-physiological doses, bolstering safety for human trials. These data, from a decade-long odyssey, validate CBG as a viable adjunct to standard care.

Meet the Minds Behind the Breakthrough

Leading the charge is Dr. Stewart Ramsay, Research Fellow at Adelaide University's School of Medicine, whose preclinical prowess drove the CLP validations. Senior author Associate Professor Richard Young, based at SAHMRI, pioneered CBG's sepsis link through proteomic analyses of ICU cohorts. Professor David Torpy, Head of Endocrine and Metabolic Medicine at Royal Adelaide Hospital, provided clinical oversight, correlating CBG variants with outcomes.

This interdisciplinary trio, spanning endocrinology, immunology, and critical care, embodies the University of Adelaide's strength in biomedicine. Affiliated with the Adelaide Medical School—one of Australia's top-ranked for clinical research—and SAHMRI, their work leverages world-class facilities like PET scanners and telemetry suites. Collaborations with AusHealth accelerate commercialization, producing clinical-grade CBG for phase I trials.

"The results were remarkable," Ramsay noted, emphasizing the 72% mortality reduction. Young added, "CBG triggers an anti-inflammatory response unrelated to cortisol transport—the first new natural agent in 70 years." Torpy stressed, "Septic shock needs new tools; CBG has minimal toxicity and life-saving potential."Explore research positions at leading Australian universities like Adelaide.

Photo by Kevin Hy on Unsplash

Beyond Sepsis: CBG's Broader Therapeutic Horizon

CBG depletion plagues not just sepsis but burns, trauma, and chronic inflammation. In severe burns, levels crash, exacerbating hypermetabolism. Preliminary data suggest CBG mitigates this, preserving cortisol homeostasis and curbing catabolism. PET imaging's injury-site targeting implies precision delivery, minimizing systemic side effects plaguing steroids like hydrocortisone.

Australian context amplifies relevance: bushfires and accidents spike burn/sepsis cases. Globally, WHO's sepsis resolution prioritizes such innovations amid rising antimicrobial resistance. With first-in-human trials imminent, CBG could redefine supportive care, complementing bundles like Surviving Sepsis Campaign protocols.

For more on careers advancing such therapies, check advice for research assistants in Australia.

Challenges Ahead: From Bench to Bedside

Translating mouse efficacy to humans demands caution—metabolic differences and dosing kinetics vary. Phase I will assess pharmacokinetics/safety in volunteers, followed by II/III in septic shock cohorts. Funding via NHMRC and philanthropics is crucial; Adelaide's track record (e.g., COVID antivirals) bodes well.

Regulatory hurdles: CBG as biologic requires GMP production. Ethical trials in moribund patients necessitate adaptive designs. Yet, minimal immunogenicity (autologous protein) and clean safety profile fast-track potential.

University of Adelaide: A Hub for Critical Care Innovation

The University of Adelaide's Adelaide Medical School ranks among Australia's elite for research impact, with SAHMRI partnerships yielding NHMRC top funding. Sepsis programs integrate genomics, proteomics, and AI for biomarker discovery. This CBG milestone builds on Torpy's HPA-axis work and Young's inflammation proteomics.

For aspiring researchers, Adelaide offers robust PhD/postdoc pipelines in endocrinology and immunology. Explore university jobs in Australia or postdoc opportunities to contribute to such frontiers.

Global Ramifications and Australian Leadership

Australia's sepsis incidence mirrors global trends—11 million deaths yearly (Lancet). CBG's universality promises equitable access, unlike pricey monoclonals. Indigenous health disparities, with higher sepsis rates, stand to benefit via targeted trials.

Timeline: Phase I 2027, pivotal II/III by 2030. Success could halve ICU mortality, saving thousands annually Down Under.

Opportunities in Sepsis Research Careers

This study spotlights demand for experts in protein therapeutics, critical care, and translational medicine. Australian universities like Adelaide seek lecturers, professors, and research fellows. Professor jobs in endocrinology abound, alongside faculty roles.

Rate professors shaping this field at Rate My Professor, seek higher ed jobs, or get career advice.

Photo by Nicholas Doherty on Unsplash

A New Dawn for Sepsis Therapy

The University of Adelaide's CBG discovery heralds hope against sepsis, blending natural biology with cutting-edge science. As trials advance, it promises to save lives, underscoring Australian research prowess. Stay tuned for updates—breakthroughs like this propel medical frontiers.